Carterra Joins the Tetra Partner Network to Advance Therapeutics Discovery

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

BOSTON, July 13, 2022 /PRNewswire/ -- TetraScience, the R&D Data Cloud company, announced today that Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, has joined the Tetra Partner Network (TPN) so that scientists can achieve greater velocity and scientific insights when analyzing the potential of antibodies as drug candidates.

Metadata

Provider:

PR Newswire

Retrieved on:

Wednesday, July 13, 2022

Information

Tags:

Cloud, Tetra, Technology, Movement, Microfluidics, Life, Antibody, SPR, Multimedia, Mab, R, ELN, PerkinElmer, TPN, LSA, CEO, COVID-19, Time, AI, Therapy, TDP, Data science, Eli Lilly, Cros, Software, Industry, Bamlanivimab, Medical device, Online shopping, Fine chemical

Geotags:

UTAH, MASSACHUSETTS, GERMANY, OCEANIA, SAN FRANCISCO, BOSTON

Organisation:

TETRASCIENCE, CARTERRA, INC.

Summary

Key Points:

"TPN is thrilled to welcome Carterra to the TPN, whose LSA instrument and software platform are creating a new standard in antibody discovery," said Alan Millar, Ph.D., Vice President, TPN.
"We are delighted to partner with TetraScience to create additional value for our customers," said Tim Germann, Chief Commercial Officer, Carterra.
"In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life.
Carterra is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates.

Carterra Joins the Tetra Partner Network to Advance Therapeutics Discovery

The Carterra LSA platform accelerates the identification of new antibody drug candidates

BOSTON, July 13, 2022 /PRNewswire/ -- TetraScience, the R&D Data Cloud company, announced today that Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, has joined the Tetra Partner Network (TPN) so that scientists can achieve greater velocity and scientific insights when analyzing the potential of antibodies as drug candidates.

"TPN is thrilled to welcome Carterra to the TPN, whose LSA instrument and software platform are creating a new standard in antibody discovery," said Alan Millar, Ph.D., Vice President, TPN. "By connecting their world-leading solution with the Tetra Data Platform (TDP), together we can help customers accelerate scientific workflows and apply advanced analytics such as AI/ML to antibody design and characterization."

Carterra's flagship LSA high-throughput surface plasmon resonance (SPR) platform and software has been adopted widely by leading biopharmaceutical, academic, and government organizations. Eli Lilly developed Bamlanivimab, the world's first COVID-19 therapeutic, on the LSA platform in a 90-day sprint. The platform can screen and analyze an entire library of thousands of antibodies in one-tenth the time of conventional approaches.

With these capabilities, the LSA produces 100 times more data creating maximum resolution. By connecting LSA output to the Tetra Data Platform, the data can be engineered into Tetra Data, a universally adoptable data format that enables seamless workflows with ELNs and provides the foundation for AI/ML.

"We are delighted to partner with TetraScience to create additional value for our customers," said Tim Germann, Chief Commercial Officer, Carterra. "With diverse and global users of our platform, we need to continue to provide an array of tools for researchers to make better decisions sooner in the drug discovery process and this alliance with TetraScience will help us accomplish that."

"Biopharma R&D needs to unify and harmonize experimental data in the cloud in order to fully capitalize on the power of AI and data science," said Patrick Grady, CEO of TetraScience. "In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life. Industry participants of all kinds – global pharmas, biotech startups, informatics providers, CROs, biopharma app companies, and more – recognize that this movement to the R&D Data Cloud must be driven by vendor-neutral and open partnerships that are deeply data-centric."

About TetraScience

TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D. For more information, please visit tetrascience.com.

About Carterra, Inc.

Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra's LSA® instrument, software, and consumables for biotherapeutic discovery and characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, PerkinElmer. For additional information, please visit www.carterra-bio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/carterra-joins-the-tetra-partner-network-to-advance-therapeutics-discovery-301585083.html

SOURCE TetraScience